N

NewLimit

Develops epigenetic medicines to extend healthspan

Senior Scientist

Full-Time
$130k - $180k/yr
Senior
PhD
San Bruno, CA, USA
In Person
Biology & BiotechTranslational Research & Bench Biology

About the job

Requirements
  • Ph.D. in cell biology, molecular biology, biochemistry or a related field or equivalent industry experience (5+ years)
  • Experience with primary cell isolation and functional characterization
  • Experience working with mouse models (e.g. kidney, cardiovascular, or cognitive disease models)
  • Experience with transgenic manipulation of primary cells either ex vivo or in vivo (e.g. using viral vectors, nucleic acid delivery)
Responsibilities
  • Develop functional assays and pre-clinical models to measure endothelial cell function
  • Collaborate with our Functional Genomics and Predictive Modeling teams to test reprogramming hypotheses at scale
  • Measure the impact of mRNA reprogramming medicines on endothelial cell function
  • Engineer in vivo nucleic acid delivery methods for endothelial cells
  • Analyze and interpret experimental data to drive pre-clinical decision making
Desired Qualifications
  • History of contributing to a drug development program at the pre-clinical or clinical development stage
  • Experience leading the design and execution of pre-clinical studies in mouse models
  • Experience with single cell genomics methods
  • Experience with pooled screening approaches using bulk or single cell read-outs (e.g. CRISPR fitness screens, Perturb/CROP-seq)

About the company

N

NewLimit

View
cbWebsite

NewLimit develops medicines that aim to extend healthy years by reprogramming the epigenome of aging cells. It works by identifying aging-related epigenetic changes using single-cell genomics, machine learning, and high-throughput functional assays, then creating interventions to reverse those changes in targeted tissues such as the immune system and liver. Compared with others, NewLimit combines a specific focus on epigenetic reprogramming with a data-driven, tissue-targeted pipeline and pursues partnerships with pharma and biotech players to develop its proprietary medicines. Its goal is to deliver a new class of medicines that significantly increases the healthspan for patients with age-related diseases.

Company Size

51-200

Company Stage

Series C

Total Funding

$650M

Headquarters

South San Francisco, California

Founded

2022

Get referred to NewLimit

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • NewLimit reported manufacturing scale-up and first restored function in old endothelial cells in July 2026.
  • September 2026 hiring spans clinical operations, LNP delivery, and translational biomarkers, signaling execution buildout.
  • Founders Fund, Thrive, Greenoaks, and Eli Lilly back a $3.1 billion valuation and runway.

What critics are saying

  • No human data exists; first clinical trials start in 2027, leaving efficacy unproven.
  • Cancer and loss-of-identity remain existential risks for epigenetic reprogramming, especially after repeat dosing.
  • Retro Biosciences, Altos Labs, and Life Biosciences are racing toward earlier human validation.

What makes NewLimit unique

  • NewLimit’s 2026 Series C raised $435M, giving rare longevity-biotech firepower.
  • Its platform uses transient mRNA transcription-factor cocktails, not permanent genomic editing.
  • Lead liver program targets a concrete disease first, alcoholic liver disease, before broader aging claims.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Parental Leave
  • Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-1%

2 year growth

-7%
BeInCrypto
Oct 16th, 2026
Elon Musk vs. Coinbase CEO: who really won tech's drinking leaderboard?

Elon Musk vs. Coinbase CEO: who really won tech's drinking leaderboard? 16 October 2026, 12:02 UTC Updated 16 October 2026, 12:02 UTC * Coinbase CEO Brian Armstrong ranked last of 39 Cheeky Pint guests. * Irish founder Will O'Brien dethroned Elon Musk at 3.31 pints per hour. * Armstrong pitched his liver-focused biotech NewLimit as the remedy. Turn everyday spending into rewards. Enjoy up to 8% cashback and up to 5% APY with the COCA Card. Order your FREE card! Coinbase CEO Brian Armstrong finished last of 39 guests on a drinking leaderboard for Stripe's Cheeky Pint podcast. However, he says the result makes him the real winner. European tech outlet ETN compiled the ranking. Its adjusted version puts Irish robotics founder Will O'Brien first at 3.31 pints per hour, about 25 times Armstrong's 0.13. Why does the Coinbase CEO call last place a win? Stripe co-founder John Collison hosts the show over pints of Guinness. ETN's first chart counted total pints, which put Elon Musk on top with three. Musk replied that he rarely drinks alcohol. The adjusted chart then weighted each drink by alcohol content and episode length, dropping him to ninth. O'Brien co-founded Ulysses, an underwater robotics startup. He drank two Guinness and a tequila shot in under 50 minutes. Afterward, he celebrated on X and took a playful shot at Musk. The Coinbase CEO saw the same data differently. In his view, the bottom of the drinking table equals first place on a "healthmaxxing" benchmark. Can a longevity startup cover the bar tab? Armstrong also offered O'Brien a remedy. He pointed to NewLimit, a biotech firm he co-founded that aims to make aging cells act young again. The Coinbase CEO has real money behind the joke. He and his co-founders seeded NewLimit with $110 million of their own capital. In June, the firm raised $435 million in a Series C round led by Founders Fund, which valued it at $3.1 billion. Its lead program targets the liver. The company plans a first human trial in 2027 for fatty liver disease, with a later phase aimed at alcohol-related liver disease. Meanwhile, Armstrong is better known for bold calls. He has argued that onchain reputation could replace credit scores and warned that a rogue AI could disrupt the internet. Still, the banter points to a broader shift in Silicon Valley, where founders fund longevity science as seriously as software. The Coinbase CEO, who expects Bitcoin to reach $400,000 by 2030, is betting the next big return may come from adding healthy years. Daily Crypto Insights Insights, news and analysis of the crypto market straight to your inbox More on Celebrity News? Disclaimer BeInCrypto is committed to unbiased, transparent reporting. This news article aims to provide accurate, timely information. However, readers are advised to verify facts independently and consult with a professional before making any decisions based on this content. Please note that our Terms and Conditions, Privacy Policy, and Disclaimers have been updated.

TradeFlock
Oct 16th, 2026
NewLimit raises $435M at $3.1B valuation as tech billionaires pour money into longevity

NewLimit, a longevity biotech co-founded by Coinbase chief executive Brian Armstrong, closed a $435 million Series C led by Founders Fund at a $3.1 billion valuation. Its first human trial, for alcohol-induced liver disease, is slated for 2027. NewLimit targets a named disease and is taking the FDA's conventional investigational new drug process, rather than selling wellness products. Armstrong is not alone. Sam Altman put $180 million into Retro Biosciences, which has raised more than $1.18 billion in total. Jeff Bezos backed Altos Labs, which leads the field with $5.56 billion in cumulative funding. Not every outsider succeeds. Analyst Sindhya Valloppillil notes that many tech-bred founders lacked clinical compliance depth and relied on wellness branding over solid science.

Biotech Insider
Sep 25th, 2026
NewLimit raises $682M to develop anti-aging drugs via cell reprogramming

NewLimit, a South San Francisco biotech co-founded by CEO Jacob Kimmel, Coinbase's Brian Armstrong and investor Blake Byers, has raised $682 million to develop anti-aging drugs based on epigenetic reprogramming. The company has been named an Endpoints 11 2026 winner. Backers include Kleiner Perkins, Founders Fund, Dimension Capital, Eli Lilly Ventures and Thrive Capital. The funding is unusually large for a private firm working on aging biology, a field that has yet to produce an approved drug. NewLimit's approach involves partially resetting gene regulation patterns in cells to restore youthful function without triggering cancer risk. The company must eventually select a specific disease indication for clinical trials, as no regulatory pathway currently treats aging itself. The capital provides runway to develop candidates before committing to human studies.

FinSMEs
Jun 3rd, 2026
NewLimit raises $435M in Series C funding.

NewLimit raises $435M in Series C funding. June 3, 2026 NewLimit, a San Francisco, California-based developer of cell reprogramming and epigenetic longevity medicines, raised $435m in Series C funding. The round was led by Founders Fund, with participation from Thrive Capital, Greenoaks, Quiet Capital, Kleiner Perkins, Abstract, Nat Friedman, Daniel Gross, Valor Equity Partners, Eli Lilly Ventures, and Human Capital. The company intends to use the funds to advance its portfolio of age-reprogramming therapies, expand its computational biology teams, and transition its lead liver-cell program into its first human clinical studies. Led by Co-Founders Brian Armstrong and Blake Byers, alongside CEO and President Jacob Kimmel, NewLimit develops an AI-driven genomics platform designed to discover transcription factor combinations that reverse cellular aging and restore metabolic, vascular, and immune health. The company has discovered a prototype medicine that reverses cellular age in old human liver cells and has accelerated its development timeline to initiate its first investigator-led human trials in late 2027. Don't just read the news. Own the data. Stop manually tracking deals. Access this round and over 100 others this week - in our structured Master Database (XML) + Weekly Intelligence PDF. [Access FinSMEs Intelligence Hub] 03/06/2026

AllSci
Jun 2nd, 2026
NewLimit raises USD 435m Series C to advance aging reprogramming medicine toward human trials.

NewLimit raises USD 435m Series C to advance aging reprogramming medicine toward human trials. June 2, 2026 South San Francisco-based NewLimit, a biotechnology company focused on longevity medicine, has closed a USD 435 million Series C funding round as it prepares to bring its first aging reprogramming therapy into human clinical trials. Founders Fund led the round, joined by new investors Thrive Capital, Greenoaks, and Quiet Capital. Returning investors included Kleiner Perkins, Abstract, Nat Friedman and Daniel Gross, Valor Equity Partners, Eli Lilly Ventures, and Human Capital, among others. The company said it plans to use the capital to advance its lead program - a prototype medicine designed to reverse cell age in old human liver cells - into first-in-human trials, which the company indicated are expected to begin next year. According to NewLimit's operating plan, the lead program is based on lipid nanoparticle-delivered RNA medicines designed to transiently express combinations of transcription factors in aged liver cells. The initial focus is alcohol-related liver disease, a setting where aging hepatocytes lose regenerative capacity and become increasingly susceptible to injury. The company has reported identifying multiple reprogramming payloads that restore youthful function in preclinical liver models with one of those selected for further development. NewLimit argues that its work represents one of the most advanced efforts in the emerging field of partial cellular reprogramming, which remains largely preclinical despite substantial investor interest. If the company proceeds on its stated timeline, it would represent one of the first direct tests of an epigenetic reprogramming approach in human subjects. The financing ranks among the largest private biotech rounds completed this year and underscores continued investor enthusiasm for longevity-focused drug development. The scale of the Series C reflects broader momentum in longevity-focused biotech, where investors have shown increasing appetite for programs targeting the biology of aging itself rather than individual age-related diseases. Eli Lilly Ventures' continued participation is notable, given Lilly's expanding interest in metabolic and age-related biology following the commercial success of its GLP-1 franchise.